title: Improvement in signs and symptoms of plaque psoriasis after 1 week of treatment with clobetasol propionate 0.05% spray.
abstract: Clobetasol propionate 0.05% spray (CPS) is a topical, super-high-potent corticosteroid indicated for the treatment of moderate to severe plaque psoriasis. Two pivotal trials of CPS investigated the efficacy and safety of treatment in subjects with moderate to severe plaque psoriasis. Overall disease severity (ODS), erythema, plaque elevation, scaling, and pruritus were assessed on a 5-point scale of 0 (clear) to 4 (severe/very severe). Overall disease severity treatment success was de!ned as achieving a score of %2 at week 2 and a score of %1 at week 4. Treatment success for all other parameters was de!ned as achieving a score of %1 at all time points. Based on Cochran-Mantel-Haenszel analysis, treatment success was achieved in the CPS group in both studies compared with vehicle after 2 weeks, but not after 1 week. Only subjects who achieved treatment success were considered for analysis. Thus, subjects who did not meet the criteria for treatment success were not examined for improvement. A post hoc analysis was conducted using all the data and the median as the measure of central tendency. It was shown that ODS, erythema, plaque elevation, scaling, and pruritus improved by 1 grade from baseline at week 1 in subjects given CPS. The data presented here suggest CPS is effective in improving the signs and symptoms of plaque psoriasis 1 week after initiating treatment.
authors: Division of Dermatology, University of Mississippi Medical Center, Jackson, MS, USA.
authors: Robert
authors: R
authors: Brodell
authors: Norman
authors: N
authors: Preston
mesh_terms: D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000336:Aerosols; D000368:Aged; D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D002990:Clobetasol / Q000008:administration & dosage / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011537:Pruritus / Q000188:drug therapy / Q000209:etiology; D011565:Psoriasis / Q000188:drug therapy* / Q000473:pathology; D012867:Skin / Q000473:pathology; D016896:Treatment Outcome; D055815:Young Adult
chemical_list: D000336:Aerosols; D000893:Anti-Inflammatory Agents; D002990:Clobetasol